![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Ledipasvir/Sofosbuvir With Ribavirin Is Safe in >600 Decompensated and Post-Liver Transplantation Patients With HCV Infection: An Integrated Safety Analysis of the SOLAR-1 and SOLAR-2 Trials
|
|
|
EASL: Ledipasvir/Sofosbuvir With Ribavirin is Safe and Efficacious in Decompensated and Post-Liver Transplantation Patients With HCV Infection: Preliminary Results of the SOLAR-2 Trial - (04/24/15)
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Didier Samuel,1 Michael Manns,2 Xavier Forns,3 Steven L. Flamm,4 K. Rajender Reddy,5 Jill Denning,6 Sarah Arterburn,6 Theo Brandt-Sarif,6
Phillip S. Pang,6 John G. McHutchison,6 Nezam Afdhal,7 Michael Charlton,8 Edward Gane,9 David Mutimer,10 Gregory T. Everson11
1Universite Paris-Sud, Villejuif, France; 2Hannover Medical School, Hannover, Germany; 3Liver Unit, IDIBAPS, CIBEREHD Hospital Clinic, Barcelona, Spain; 4Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; 5University of Pennsylvania School of Medicine, Philadelphia, Pennslvania, USA;
6Gilead Sciences, Inc., Foster City, California, USA; 7Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA; 8Intermountain Medical Center, Murray, Utah, USA; 9University of Auckland, New Zealand; 10Queen Elizabeth Hospital and University of Birmingham, Birmingham, England; 11University of Colorado Denver, Aurora, Colorado, USA
![EASL1.gif](../images/042815/042815-5/EASL1.gif)
![EASL2.gif](../images/042815/042815-5/EASL2.gif)
![EASL3.gif](../images/042815/042815-5/EASL3.gif)
![EASL4.gif](../images/042815/042815-5/EASL4.gif)
![EASL5.gif](../images/042815/042815-5/EASL5.gif)
![EASL6.gif](../images/042815/042815-5/EASL6.gif)
![EASL7.gif](../images/042815/042815-5/EASL7.gif)
![EASL8.gif](../images/042815/042815-5/EASL8.gif)
![EASL9.gif](../images/042815/042815-5/EASL9.gif)
![EASL10.gif](../images/042815/042815-5/EASL10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|